Stock RCUS ARCUS BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-03 pm EDT 		5-day change 1st Jan Change
15.7 USD +1.29% Intraday chart for Arcus Biosciences, Inc. +0.96% -17.80%
Mar. 12 Transcript : Arcus Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:35 PM
Feb. 29 Arcus Biosciences Insider Sold Shares Worth $1,177,967, According to a Recent SEC Filing MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
BU
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
BU
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates
BU
Gilead and Arcus Announce Amended Collaboration and Equity Investment
BU
Gilead and Arcus Announce Amended Collaboration and Equity Investment
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Arcus Biosciences, Inc. - Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naive Metastatic Pancreatic Cancer
AQ
Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
BU
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RCUS Stock
  4. News Arcus Biosciences, Inc.
  5. Press Releases